AAM
REGN icon

Azzad Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Azzad Asset Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$758K Buy
+981
New +$751K 0.08% 257
2022
Q4 		– Sell
-3,093
Closed -$1.97M – 372
2022
Q3 		$1.97M Sell
3,093
-2,000
-39% -$1.26M 0.2% 170
2022
Q2 		$3.09M Buy
5,093
+2,555
+101% +$1.66M 0.31% 112
2022
Q1 		$1.77M Sell
2,538
-789
-24% -$499K 0.26% 154
2021
Q4 		$2.1M Buy
3,327
+32
+1% +$19.7K 0.28% 140
2021
Q3 		$1.99M Buy
3,295
+74
+2% +$45.9K 0.29% 138
2021
Q2 		$1.8M Sell
3,221
-100
-3% -$50.7K 0.27% 155
2021
Q1 		$1.57M Buy
3,321
+233
+8% +$113K 0.26% 158
2020
Q4 		$1.49M Sell
3,088
-3
-0.1% -$1.62K 0.27% 147
2020
Q3 		$1.73M Buy
3,091
+567
+22% +$344K 0.36% 110
2020
Q2 		$1.57M Sell
2,524
-583
-19% -$331K 0.37% 97
2020
Q1 		$1.52M Sell
3,107
-2,437
-44% -$1.01M 0.44% 75
2019
Q4 		$2.71M Buy
5,544
+56
+1% +$18.8K 0.32% 108
2019
Q3 		$2.4M Buy
+5,488
New +$1.62M 0.3% 118
2017
Q2 		– Sell
-652
Closed -$253K – 305
2017
Q1 		$253K Hold
652
– – 0.1% 242
2016
Q4 		$239K Hold
652
– – 0.1% 225
2016
Q3 		$262K Hold
652
– – 0.11% 227
2016
Q2 		$228K Hold
652
– – 0.1% 231
2016
Q1 		$235K Sell
652
-1
-0.2% -$412 0.1% 226
2015
Q4 		$354K Sell
653
-2
-0.3% -$1.08K 0.17% 193
2015
Q3 		$305K Hold
655
– – 0.16% 208
2015
Q2 		$334K Sell
655
-855
-57% -$417K 0.17% 211
2015
Q1 		$682K Hold
1,510
– – 0.33% 126
2014
Q4 		$620K Sell
1,510
-953
-39% -$375K 0.33% 123
2014
Q3 		$888K Hold
2,463
– – 0.51% 50
2014
Q2 		$696K Sell
2,463
-525
-18% -$156K 0.42% 98
2014
Q1 		$897K Buy
2,988
+37
+1% +$11.4K 0.59% 32
2013
Q4 		$812K Buy
2,951
+43
+1% +$12.4K 0.59% 44
2013
Q3 		$910K Hold
2,908
– – 0.75% 20
2013
Q2 		$694K Buy
+2,908
New +$677K 0.6% 42

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Azzad Asset Management's REGN Position: Q1 2026 in Review

Azzad Asset Management opened a new position in Regeneron Pharmaceuticals (REGN) in Q1 2026: 981 shares worth $758K. The stake represents 0.08% of the portfolio and ranks #257 among its holdings. This is a return to the name: Azzad Asset Management previously reported a position in REGN as recently as Q3 2022.

Azzad Asset Management first reported a position in REGN in Q2 2013 and has held it in 30 quarters since. The position peaked at $3.09M in Q2 2022. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Azzad Asset Management held 981 shares of Regeneron Pharmaceuticals worth $758K as of Q1 2026.
  • Regeneron Pharmaceuticals was a new Azzad Asset Management position in Q1 2026.
  • Regeneron Pharmaceuticals made up 0.08% of Azzad Asset Management's portfolio in Q1 2026, its #257 holding.
  • Azzad Asset Management first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 30 quarters since.
  • Azzad Asset Management's Regeneron Pharmaceuticals position peaked at $3.09M in Q2 2022.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Azzad Asset Management's 13F filing for Q1 2026, filed 30 Apr 2026.